The FDA has given the go-ahead to Axsome’s Auvelity for the treatment of agitation in patients with dementia associated with Alzheimer’s disease, marking the first non-antipsychotic drug to be cleared for this indication.

Axsome closed Thursday’s trading session up nearly 13%, hitting a share price of $207.75.

“We see Auvelity’s expansion into [Alzheimer’s disease agitation] as a large revenue opportunity,” analysts at William Blair wrote in a Thursday note to investors, estimating that peak sales could reach more than $2.1 billion in this indication for Axsome.